Anti-TNFα Biologics in the Pharmacotherapy of Rheumatoid Arthritis: Effectiveness and Safety of Infliximab, Adalimumab and Etanercept

Rheumatoid arthritis (RA) is a chronic inflammatory disease of unknown etiology. Traditionally, pharmacotherapy of RA involved non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs). However, focus now has been diverted to biologic DMARDs. Tumor necrosis factor alpha (TNFα) plays pleiotropic roles in RA pathogenesis. Hence, anti-TNF biologics offer attractive therapeutic utility. Literature contains...